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Abstract
Background and Objective: Inclusion in systematic reviews is one important component in judging the potential impact of
clinical studies upon practice and hence the ‘value for money’ of spending for clinical research. This study aims to quantify
the distribution of countries of origin of clinical studies used in Cochrane Reviews (CRs), and to link these data to the size of
a country and to its spending on research.
Methods: Random sample of publications used for CRs published in Issue 1 2008 and of publications used in CRs in the field
of complementary and alternative medicine (CAM). Publications without original data were excluded. Likely countries of
origin determined based on abstracts/full texts. CIA World Factbook (population data) and OECD database (economic data)
were used.
Results: 1,000 random entries out of 140,005 references available in all specialities. In 876 (91.4%) of 959 eligible studies,
country of origin was determined. The USA was the leading contributor (36.0% of the studies), followed by UK (13.4%),
Canada (5.3%), Australia and Sweden (3.7%). In the CAM sample, country of origin was determined in 458 (93.5%) of 497
assessed studies. Again, the USA was the leading contributor (24.9%), with China also emerging as a significant contributor
(24.7%) in this field. For both samples, the contribution of smaller countries (especially Scandinavian countries, Greece, and
Ireland) became more noteworthy when considered in relation to population size and research spending.
Conclusions: Our results support the leading roles of both the USA and the UK in publishing clinical papers. The emerging
role of China can be seen, particularly related to CAM studies. Taking into account size of population and economic power,
countries like France, Germany, Italy, and Spain provide small contributions. In contrast, smaller countries like Australia,
Denmark, Finland, Ireland, New Zealand, and Sweden also play major roles.
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Introduction
Back in 1747, the Scottish naval surgeon James Lind conducted
one of the first controlled clinical trials (CCT) [1]. Since the end of
the Second World War hundreds of thousands of CCTs and
randomised controlled trials (RCTs) have been conducted all over
the world [2,3]. Today, clinical trials can be seen as the backbone
of systematic reviews [4]. Systematic reviews have a decisive role in
clinical decision making [5,6].
Studies assessing the geographical distribution of clinical
research activity have confirmed the leading role of the USA in
publishing scientific papers in various fields: in the top 50
biomedical journals [7], clinical cardiology [8], clinical radiology
[9], clinical oncology [10], drug trials [11] and biomedical
research [12]. In addition, various publications on the contribution
of countries to publications of specific journals are available
[13,14].
To date, we are aware of only one study that has examined the
production of RCTs and CCTs per country across all specialities
and journals [15]. The authors of this study used ‘‘Clinical Trials’’,
formerly known as ‘‘Cochrane Central Register on Controlled
Trials’’ (CENTRAL), in the Cochrane Library to create a ranking
of countries with respect to the numbers of published RCTs and
CCTs [16]. In addition, they tried to assess the relationship
between the number of inhabitants per country and publication
rates by the performance of an ecological study.
Based on this concept of Gluud and Nikolova [15], we have
evaluated the studies used for systematic reviews published by the
Cochrane Collaboration. The ‘‘Cochrane Database of Systematic
Reviews’’ (‘‘Cochrane Reviews’’) as part of the Cochrane Library
contains 3,372 reviews and 1,776 protocols for reviews (Issue 1
2008).
As thorough searches are conducted for Cochrane Reviews
(including handseaching and searches for non-English studies),
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they are likely to include a high proportion of the available
studies in any clinical field [3]. Usage of a clinical study in
systematic reviews can be used as a proxy for quality and the
practical value of the trial. Systematic reviews and hence the
studies included in them form the evidence body supporting any
clinical guidance, such as guidelines, evidence-based patient
information and websites, and reimbursement decisions (health
technology assessments).
Our study aims to determine the contribution of clinical studies
per country across all specialties and to examine the production of
clinical studies in the field of complementary and alternative
medicine (CAM). We have also assessed the relationships between
the contribution rate and the population size and spending on
research and development of each country.
Methods
Literature search
The database of studies used for Cochrane Reviews published in
Issue 1 2008 of the Cochrane Database of Systematic Reviews was
used as a source of data. This database includes all studies
retrieved for Cochrane Reviews, those which were finally included
in reviews, those which were excluded as well as cited publications.
The sample of CAM related studies was created from a selection of
Cochrane Reviews, identified as CAM related reviews by the
complementary and alternative medicine field of the Cochrane
Collaboration [17].
All stages of study selection and data extraction were done by
one of three reviewers (RW, SR or MB) and checked
independently by a second reviewer (RW, SR or MB). Any
disagreement during the selection, extraction, and assessment
process was resolved by discussion and consensus.
Study selection
Samples of studies were drawn using the ‘‘SURVEYSELECT’’
command in SAS 9.1.3 Service Pack 4 and SPSS for Windows
11.5.1.
Study samples were screened for fulfilling the inclusion criteria.
Eligible studies were included in the process of assessing the
country of origin.
Figure 1. Flow diagram according to the QUOROM-statement [27] with the total number of studies used for Cochrane Reviews and
the number included in the present study. CAM=Complementary and alternative medicine.
doi:10.1371/journal.pone.0018798.g001
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Inclusion criteria
Publications assessed for inclusion in Cochrane Reviews were
included. In a first step, we excluded studies awaiting assessment
or marked as ongoing trials. Secondly, we excluded reviews,
studies focussing on economical or methodological aspects,
publications without original data (like editorials, comments,
letters to the editor), studies on animals and studies without
reference.
Data extraction and quality assessment
The abstract and/or full text of each included study was
checked to determine the likely country of origin. The decision was
based on participating centres and hospitals, the responsible ethics
committee, the funding source, and the affiliation of the authors.
Cases in which the likely country of origin could not be
determined were excluded; this included multicentre studies
conducted in various countries where no lead country could be
identified. Accordingly, studies with a clearly identifiable leading
country were only counted once.
Various sources were used to gather information about the
studies: original publications, data from trial registries, Google
Scholar, ISI Web of Knowledge, and the websites of the journals
publishing included studies. If necessary, we contacted the authors
of related Cochrane Reviews to obtain further information.
The CIA World Factbook [18] was used to extract data on
population of countries. The economic data were drawn from the
OECD Statistics Portal of the Organisation for Economic Co-
operation and Development (OECD) [19]. We calculated the
spending on research and development (R&D) using the Gross
Domestic Product (GDP) and the percentage spent on R&D.
Data analysis
We used MicrosoftH Office Excel 2007 for data analysis and for
presentation of the data.
Results
Description of search and selection process
The Cochrane Reviews published in Issue 1 2008 contained
140,005 references to studies. After exclusion of studies awaiting
assessment and ongoing studies, 134,144 were available for
assessment. From this data set, we randomly sampled 1,000
studies across all specialities and 500 CAM-related studies. After
checking for studies meeting the exclusion criteria, 959 and 497
studies respectively were available for data assessment (Figure 1).
Country of origin
We were able to identify the likely country of origin of 876 of
959 studies across all specialities (91.3%), and 458 of 497 CAM-
related studies (92.2%).
Across all specialities, the USA published most CCTs and
RCTs (n = 315 of 876, 36.0%), followed by the United Kingdom
(UK, 117, 13.4%), Canada (46, 5.3%), Australia (32, 3.7%), and
Sweden (32, 3.7%).
When only CAM-related studies were considered, the USA
remained the country with the highest number of publications
(n = 114 of 458, 24.9%), followed by China (113, 24.7%), the UK
(59, 12.9%), Germany (17, 3.7%) and Italy (13, 2.8%). These
results are presented in Table 1.
Number of studies and population
We assessed the relationship between the number of studies
originating from each country and population size. Table 2
presents the number of studies published per one million
inhabitants. Smaller countries generally made the greatest
contribution, relative to size: Denmark with a population of 5.5
million published 3.82 studies per million inhabitants, followed by
Sweden (9.0; 3.56), Finland (5.2; 3.27), the UK (61.1; 1.92) and
Ireland (4.2; 1.66).
When only CAM-related studies were considered, Denmark
(5.5; 2.00) remained the leading country, followed by Finland (5.2;
1.15), UK (61.1; 0.97), Sweden (9.0; 0.89) and Norway (4.6; 0.87).
Number of studies and spending on research &
development
We also assessed the relationship between the scientific spending
of the member states of the OECD and the number of studies
published. The results are presented in table 3.
Based on studies produced per billion US-Dollar of research
and development spending, Denmark (4.21) achieved the highest
Table 1. Table showing the first 30 entries of likely country of
origin for studies within all specialities (left) and CAM-related
studies (right).
Studies within all specialities CAM-related studies
Country n= % Country n= %
USA 315 36.0 USA 114 24.9
United Kingdom 117 13.4 China 113 24.7
Canada 46 5.3 United Kingdom 59 12.9
Australia 32 3.7 Germany 17 3.7
Sweden 32 3.7 Italy 13 2.8
Germany 31 3.5 Denmark 11 2.4
Italy 30 3.4 Netherlands 10 2.2
Netherlands 25 2.9 Australia 10 2.2
France 24 2.7 Canada 10 2.2
Denmark 21 2.4 Japan 10 2.2
Japan 19 2.2 India 9 2.0
China 17 1.9 Sweden 8 1.7
Finland 17 1.9 Finland 6 1.3
India 14 1.6 France 6 1.3
Spain 12 1.4 Israel 5 1.1
Israel 10 1.1 Hungary 5 1.1
Switzerland 8 0.9 Norway 4 0.9
Belgium 7 0.8 Taiwan 4 0.9
Ireland 7 0.8 Poland 4 0.9
Austria 6 0.7 Switzerland 3 0.7
Norway 6 0.7 Romania 3 0.7
South Africa 6 0.7 Spain 3 0.7
Greece 5 0.6 South Africa 3 0.7
Mexico 5 0.6 Nigeria 3 0.7
Turkey 5 0.6 Brazil 3 0.7
Brazil 3 0.3 New Zealand 2 0.4
Czech Republic 3 0.3 Austria 2 0.4
Hungary 3 0.3 Belgium 2 0.4
New Zealand 3 0.3 Russia 2 0.4
Taiwan 3 0.3 Chile 2 0.4
doi:10.1371/journal.pone.0018798.t001
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productivity, followed by the UK (3.03), Greece (2.76), Finland
(2.67) and Sweden (2.63).
When only CAM-related studies were considered, Hungary
(2.73) was the leading country, followed by Denmark (2.21), the
UK (1.53), New Zealand (1.50) and Chile (1.49).
Discussion
Summary of findings
The USA and the UK are major contributors to the worldwide
pool of clinical studies. China plays an important role in the field
of complementary and alternative medicine. However, in relation
to size of population and spending on research and development
smaller countries like Australia, Denmark, Finland, Ireland, New
Zealand, and Sweden also play major roles.
Trial registers proved to be a poor source of additional
information on the trials in our sample. Only a small proportion
of trials were indexed in these databases. This reflects the fact, that
the usage of trials registers was low until the statement of the
International Committee of Medical Journal Editors (ICMJE) in
2004 [20], which increased the willingness for trial registration
[21]; this effect is accentuated by the natural delay between
conduct of trials and their inclusion in systematic reviews.
Limitations and strengths
We decided to restrict our analysis to studies used for reviews
conducted within the framework of the Cochrane Collaboration
knowing that many other reviews are undertaken and published
elsewhere [22]. These reviews could include studies not used in
Cochrane Reviews. In our opinion, this should not limit the
generalisability of our findings. Cochrane Reviews use robust, well
documented searching methods and are likely to include a high
proportion of the available studies in any clinical field [3,23]. In
addition, included studied underwent a rigorous quality assess-
ment. Due to handsearching in various journals done by the
Cochrane Collaboration, a number of non-English papers not
Table 2. Number of studies per million inhabitants per country within all specialities (left) and CAM-related studies (right).
Studies within all specialities CAM-related studies
Country Population1 n/Pop2 Country Population1 n/Pop2
Denmark 5.5 3.82 Denmark 5.5 2.00
Sweden 9.0 3.56 Finland 5.2 1.15
Finland 5.2 3.27 UK 61.1 0.97
UK 61.1 1.92 Sweden 9.0 0.89
Ireland 4.2 1.66 Norway 4.6 0.87
Australia 21.2 1.51 Israel 7.2 0.69
Netherlands 16.7 1.50 Netherlands 16.7 0.60
Israel 7.2 1.39 Hungary 9.9 0.50
Canada 33.4 1.38 Slovenia 2.0 0.50
Norway 4.6 1.30 New Zealand 4.2 0.48
Switzerland 7.6 1.05 Australia 21.2 0.47
USA 307.2 1.03 Switzerland 7.6 0.40
Austria 8.2 0.73 USA 307.2 0.37
New Zealand 4.2 0.71 Canada 33.4 0.30
Belgium 10.4 0.67 Austria 8.2 0.24
Gambia 1.7 0.60 Ireland 4.2 0.24
Italy 58.1 0.52 Italy 58.1 0.22
Slovenia 2.0 0.50 Germany 82.3 0.21
Greece 10.7 0.47 Belgium 10.4 0.19
Singapore 4.6 0.44 Taiwan 22.9 0.18
Germany 82.3 0.38 Libya 6.3 0.16
France 64.0 0.38 South Africa 19.0 0.16
South Africa 19.0 0.32 Ecuador 14.6 0.14
Hungary 9.9 0.30 Serbia 7.3 0.14
Spain 40.5 0.30 Romania 22.2 0.14
Czech Republic 10.2 0.29 Chile 16.6 0.12
Croatia 4.4 0.23 Poland 38.4 0.10
United Arab Emirates 4.7 0.21 Czech Republic 10.2 0.10
Portugal 10.2 0.20 France 64.0 0.09
Slovakia 5.4 0.19 Greece 10.7 0.09
1Inhabitants in Million.
2Number of studies/Million inhabitants.
doi:10.1371/journal.pone.0018798.t002
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included in other databases are part of the database searched for
this project [23].
It should be noted that some clinical questions have been
addressed by one or two high quality trials providing clear
evidence in favour or against the use of interventions. In these
cases systematic reviews might not have been undertaken. In our
view, this should not influence the findings of this study as we used
a large and representative sample of clinical studies.
Compared to total volume of published clinical studies worldwide,
we included only small proportion of relevant studies. Due to the
play of chance, our results might therefore be flawed. However, due
to random sampling used for these studies systematic bias is unlikely.
In addition, we have decided to use the number of studies rather
than the number of patients included in each study as this was not
possible with the available data. While it could be argued that this
might influence the findings presented in this paper (e.g. number
of publications/population favours the production of smaller
trials), we hope to have avoided measuring trial participation.
However, it would be interesting for future studies to address this
point and to allow comparisons between the two measures.
Table 3. Spending on research and development of each country and ‘‘studies for money’’ within all specialities (left) and CAM-
related studies (right).
Studies within all specialities CAM-related studies
Country GDP1 R&D2 n/R&D3 Country GDP1 R&D2 n/R&D3
Denmark 196.3 2.54 4.21 Hungary 188.6 0.97 2.73
United Kingdom 2168.1 1.786 3.03 Denmark 196.3 2.54 2.21
Greece 318.1 0.57 2.76 United Kingdom 2168.1 1.786 1.53
Finland 183.6 3.47 2.67 New Zealand 114.8 1.165 1.50
Sweden 334.8 3.63 2.63 Chile 199.85 0.674 1.49
Ireland 196.2 1.36 2.62 Slovenia 54.0 1.58 1.17
New Zealand 114.8 1.165 2.25 Poland 609.4 0.566 1.17
Netherlands 642.4 1.73 2.25 China 7055.1 1.49 1.07
Australia 794.6 2.016 2.00 Norway 251.7 1.57 1.01
Slovak Republic 108.4 0.47 1.96 Finland 183.6 3.47 0.94
Canada 1269.6 1.89 1.92 Netherlands 642.4 1.73 0.90
Hungary 188.6 0.97 1.64 South Africa 463.3 0.956 8 0.68
Norway 251.7 1.57 1.52 Sweden 334.8 3.63 0.66
Italy 1802.2 1.14 1.46 Italy 1802.2 1.146 0.63
South Africa 463.3 0.956 8 1.36 Australia 794.6 2.016 0.63
Slovenia 54.0 1.58 1.17 Israel 188.9 4.74 0.56
Israel 188.9 4.74 1.12 Greece 318.1 0.57 0.55
Belgium 375.8 1.89 0.99 Canada 1269.6 1.89 0.42
Turkey 960.3 0.586 0.90 India 3092.1 0.714 0.41
Switzerland 308.6 2.94 0.89 Ireland 196.2 1.36 0.37
United States 13741.6 2.687 0.86 Switzerland 308.6 2.94 0.34
Czech Republic 248 1.53 0.79 United States 13741.6 2.687 0.31
Austria 308.7 2.56 0.76 Belgium 375.8 1.89 0.28
Chile 199.85 0.674 0.75 Czech Republic 248 1.53 0.26
Mexico 1479.9 0.465 0.73 Austria 308.7 2.56 0.25
Spain 1417.4 1.26 0.71 Germany 2829.1 2.53 0.24
Portugal 242 1.18 0.70 Turkey 960.3 0.586 0.18
India 3092.1 0.714 0.64 Spain 1417.4 1.26 0.18
Poland 609.4 0.566 0.59 Brazil 1833.6 1.026 0.16
France 2078 2.08 0.56 France 2078 2.08 0.14
Latest available data were used. If not stated otherwise. data are of 2007.
1Gross Domestic Product in billion US-Dollar;
2Gross domestic expenditure on R&D;
3Studies per billion US-Dollar spent on R&D;
42004;
52005;
62006;
7R&D conducted by state and local governments is excluded;
8Due to the lack of a comprehensive business register in South Africa. R&D expenditure may be underestimated by 10% to 15%.
doi:10.1371/journal.pone.0018798.t003
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Our classification of likely country of origin was based on
information given by numerous electronic databases and data
given within the trial publications. In order to resolve uncertain
cases we have used consensus. However, we acknowledge that
even this consensus decision may be subjective and flawed. In
addition, the accuracy of our decisions was linked to the quality of
the trial publication. This may be independent of quality of the
trial in whole.
We used gross domestic expenditures on research and
development in general as a surrogate for spending in clinical
research. This includes disciplines other than medical sciences and
is therefore only an estimate of real spending on clinical research.
However, in our opinion, this was the best way to ensure
comparability of the different countries.
Furthermore, the data on R&D spending derived from the
OECD database is partially outdated. Some of the stated
information is older than other data used for table 3 of this paper.
However, we do not believe that this variation is likely to have a
major impact on the results.
To our knowledge, this is the first study to examine the
production of clinical studies in the field of complementary and
alternative medicine.
Additionally to previous publications, we linked the data on the
number of publications in relation to national spending on
research and development.
Findings in context
We are able to confirm the main results of the study published
by Gluud and Nikolova [15]. It is remarkable that smaller
countries are able to publish more clinical studies than large
countries with high GDP like China, France, Germany, Italy,
Japan or Spain.
One could argue that language bias prevents publication by
researchers from these countries in major international journals
[24]. However, efforts of the Cochrane Collaboration lead to an
inclusion of a substantial number of non-English language
publications [23]. This argument is supported by the number of
publications from China, which were identified in the area of the
complementary and alternative medicine. However, this might be
influenced by an increased activity and interest of Chinese
researchers in the field of CAM.
Implications
Despite the known differences in research funding between the
USA and the European Union [25], there are differences between
countries in Europe. Smaller countries like Denmark, Finland,
Norway and The Netherlands produce more clinical studies than
bigger countries like France, Germany, Italy and Spain. This
could be due to a high proportion of R&D spending used for
clinical research, a better organisation of research, or more
focussed research programmes within these smaller countries.
Significantly, discussion has started about a reform of countries’
funding schemes [26].
Conclusions
Our results support the leading roles of the USA and the UK in
publishing clinical papers. The potential for a future important
role for China can be seen when examining CAM studies. Taking
into account size of population and economic power, countries like
France, Germany, Italy, and Spain make small contributions. In
contrast, smaller countries like Australia, Denmark, Finland,
Ireland, New Zealand, and Sweden play major roles.
Research on factors explaining observed differences between
countries could contribute to the design of future funding schemes
and increase the efficiency of research spend.
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